Condition (MeSH)
Loiasis
ClinicalTrials.gov lists 12 trials for Loiasis or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
12 of the 12 trials are tagged with Loiasis itself; the rest are tagged with a narrower condition beneath it.
When did Loiasis trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 3 |
| 2022 | 2 |
| 2021 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2012 | 1 |
| 2010 | 1 |
No forecast is made for this condition: it averages 1.2 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Loiasis trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 4 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Phase 4 | 2 |
| Not applicable | 2 |
| Observational | 2 |
How many Loiasis trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 1 |
| Completed | 7 |
| Terminated | 1 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Loiasis trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 3 |
| Programme National de Lutte contre l'Onchocercose, Republic of the Congo | 3 |
| University Hospital, Angers | 1 |
Which drugs are being tested for Loiasis? (6)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Ivermectin | 3 |
| Diethylcarbamazine | 2 |
| Reslizumab | 1 |
| Imatinib | 1 |
| Albendazole | 1 |
Showing 5 of 6 drugs.
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Biological samples collection | 1 |
| LEV 1 mg/kg | 1 |
| LEV 2,5 mg/kg | 1 |
| LEV 1,5 mg/kg | 1 |
| Levamisole 3 days | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Loiasis trials report? (3)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Neutropenia | 2 | 1 |
| Hypertension | 1 | 1 |
| Pulmonary embolism | 1 | 1 |
Which publications cover Loiasis? (23)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Safety and efficacy of 3- and 5-day regimens of levamisole in loiasis: a randomized, placebo-controlled, double-blind clinical trial. | Nature communications | 2025 | Yes |
| A Novel, Highly Sensitive Nucleic Acid Amplification Test Assay for the Diagnosis of Loiasis and its Use for Detection of Circulating Cell-Free DNA. | The Journal of infectious diseases | 2023 | Yes |
| Safety and Efficacy of Levamisole in Loiasis: A Randomized, Placebo-controlled, Double-blind Clinical Trial. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2022 | Yes |
| Distinct loiasis infection states and associated clinical and hematological manifestations in patients from Gabon. | PLoS neglected tropical diseases | 2022 | Yes |
| Infection-associated Immune Perturbations Resolve 1 Year Following Treatment for Loa loa. | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2021 | Yes |
Showing 5 of 23 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Loiasis | Point prevalence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Loiasis | Point prevalence | >1 / 1000 | Specific population | Not stated | Unspecified |
| Loiasis | Point prevalence | >1 / 1000 | Specific population | Not stated | Exact |
| Loiasis | Point prevalence | <1 / 1 000 000 | Europe | Not stated | Unspecified |
| Loiasis | Point prevalence | >1 / 1000 | Specific population | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Loiasis | 2404 | Exact | Orphadata Science knowledge files, Product 1 |
| Loiasis | 2404 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.